Press Releases June 2, 2025: MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency…MaaT PharmaJune 2, 2025
Press Releases May 14, 2025: MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European…MaaT PharmaMay 14, 2025
Press Releases May 14, 2025: MaaT Pharma to Hold Annual General Meeting on June 20, 2025 MaaT Pharma to Hold Annual General Meeting on June 20, 2025 Lyon, France, May 14,…MaaT PharmaMay 14, 2025
Press Releases May 13, 2025: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 Positive…MaaT PharmaMay 13, 2025
Press Releases May 12, 2025: MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral…MaaT PharmaMay 12, 2025
Press Releases April 28, 2025: MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity…MaaT PharmaApril 28, 2025
Press Releases April 14, 2025: Availability of MaaT Pharma’s 2024 Universal Registration Document (URD) Availability of MaaT Pharma’s 2024 Universal Registration Document (URD) Lyon, France, April 14, 2025 -…MaaT PharmaApril 14, 2025
Press Releases April 8, 2025: MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033…MaaT PharmaApril 8, 2025
Press Releases April 7, 2025: MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co Lyon,…MaaT PharmaApril 7, 2025
Press Releases April 4, 2025: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…MaaT PharmaApril 4, 2025